Skip Navigation

Find a Doctor

Find a Researcher

Researchers

Sangeeta Ray, M.S., Ph.D.

Photo of Dr. Sangeeta Ray, M.S., Ph.D.
  • Associate Professor of Radiology and Radiological Science
Female

Background

Dr. Sangeeta Ray is an Associate Professor of Radiology and Radiological Science at Johns Hopkins, School of Medicine. Dr. Ray has been working in the field of developing new agents for the noninvasive molecular imaging and therapy over the last 15 years. Dr. Ray has pioneered the development of radiometal-labeled low-molecular-weight imaging agents for SPECT and PET targeting prostate-specific membrane antigen (PSMA), an important molecular target for advanced metastatic castration-resistant prostate cancer and many solid tumor neovasculature. She has been also involved in developing PSMA-based agents for MR, optical, Raman and photoacoustic imaging. The current focus of her research lab is in the development of targeted radionuclide therapy for prostate cancer and other solid tumor malignancies.

...read more

Titles

  • Associate Professor of Radiology and Radiological Science
  • Associate Professor of Oncology

Departments / Divisions

Education

Degrees

  • Ph.D., Jadavpur University (India) (1999)
  • M.S., Jadavpur University (India) (1995)
  • B.S., University of Burdwan (India) (1993)

Research & Publications

Research Summary

The long-term research focus of my laboratory is to develop new imaging and therapeutic agents and nanomaterials that could contribute immensely to detection, treatment, and prevention of cancer and related diseases. Along that direction, we will continue to develop necessary chemistry and bioconjugate techniques for important cellular and molecular targets for clinical translation to improve patient-specific diagnosis and treatment option. In addition to radiopharmaceutical based SPECT and PET imaging agents, our research projects are directed to develop contrast agents for MR, fluorescence, CT and photoacoustic imaging modalities. Recent projects are also directed to develop radiotheranostics for targeted radionuclide therapy of advanced metastatic cancers.

Since 2006 my research work has been focused on developing new imaging and therapeutic agents targeting the prostate-specific membrane antigen (PSMA). We have generated extensive structure-activity relationships in that regard and has contributed to several important firsts in this area, namely the design rules and synthesis of the 1st radiometallated (2008), 1st successful in vivo optical (2009) and the 1st Gallium-68-labeled (2010), the 1st dual modality SPECT-optical (2011), the 1st gadolinium magnetic resonance imaging (MR) (2015) and the 1st Chemical-Exchange Saturation Transfer (CEST) MR (2018) PSMA-targeted probes. Our Ga-68/Lu-177-labeled theranostic agent is currently undergoing multi-center phase 1 trials sponsored by Advanced Accelerator Applications/Novartis.

Lab

Our Lab's research interest is directed towards the development of metal-based molecular imaging agents for positron emission tomography (PET), single-photon emission computed tomography (SPECT), magnetic resonance (MR), optical (fluorescence and photoacoustic) as well as for multimodality imaging techniques. With a major focus on prostate-specific membrane antigen (PSMA), she has designed and synthesized more than fifty agents for SPECT, PET, optical and MR imaging modality, many of those agents are first-in-class imaging agents. Currently, her lab has been focused on evaluating and optimizing several therapeutic radiometal-based agents including Lu-177, Bi-213, Pb-212 and Ac-225 for the imaging and treatment ('theranostics') for metastatic prostate cancer and several lethal malignancies.

Selected Publications

View all on Pubmed

Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox J, Hilton J, Lupold SE, Kozikowski AP, Pomper MG. Synthesis and evaluation of technetium-99m-and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008;51:4504-4517

Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Green G, Fox JJ, Horti A, Mease RC, Pomper MG. Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010;53:5333-5341

Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Foss CA, Green G, Fox JJ, Lupold SE, Mease RC, Pomper MG. Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angew Chem Int Ed 2011; 50:9167-9170

Banerjee SR*, Minn I, Kumar V, Josefsson A, Lisok A, Brummet M, Chen J, Kiess AP, Baidoo K, Brayton C, Mease RC, Brechbiel M, Sgouros G, Hobbs RF, Pomper MG. Preclinical evaluation of Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer. J Nucl Med. 2019 (online)

Banerjee SR*, Kumar V, Lisok A, Chen J, Minn I, Brummet M, Boinapally S, Cole M, Ngen E, Wharram B, Brayton C, Hobbs R, Pomper MG. Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy. Eur J Nucl Med Mol Imaging. 2019 (online)

Patents

Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase IX (second generation)
Patent # JHU C14017 | 01/01/2016

Yang X, Minn I, Ray S, Rowe S, Gorin M, , Mease R, Allaf M, Pomper MG. 

Prostate-specific membrane antigen targeted high-affinity agents for endo radiotherapy of prostate cancer.
Patent # JHU C14083

Pomper MG, Ray S

PSMA targeted reversed carbamates and methods of use thereof.
Patent # WO 2016065145 A2 20160428. | 01/01/2016

Pomper MG, Mease RC, Ray S,Chen Y, Yang X, Attardo, Georgio.

New scaffolds and multifunctional intermediates for imaging psma and cancer therapy.
Patent # WO 2016065142 A2 20160428. | 01/01/2016

Pomper MG, Mease RC, Ray S,Chen Y, Yang X. 

Salicylic Acid-based Polymeric CEST Contrast agents for molecular imaging of prostate-specific membrane antigen.
Patent # C13062 | 01/01/2015

Yang X, Song X, Ray S, Pomper MG, McMahon M. 

Prostate-specific Membrane Antigen Targeted Plasmon-enhanced Raman Spectroscopy Reporters for Molecular Imaging of Prostate Cancer.
Patent # JHU C13637 | 01/01/2015

Barman I, Li M, Ray S, Pomper MG. 

Preparation of metal or radiometal-labeled urea- and carbamate-based PSMA inhibitors for PSMA-targeted imaging and radiotherapy.
Patent # WO 2015171792 A1 20151112 | 01/01/2015

Ray S,Pomper MG, Meade TJ, Mease RC, Chen Y, Yang X. 

PSMA-targeting compounds and uses thereof. United States Patent US2015/010438A
Patent # WO 2010108125 A2 20100923 | 01/01/2015

Pomper MG, Mease RC.; Ray S, Chen Y. 

Azole heterocycles for MRI contrast and pH sensing.
Patent # WO 2014186737 A1 20141120 | 01/01/2014

Yang X, Song X, Ray S, Pomper MG, McMahon M.

Salicylic acid, salicylic acid analogs and anthranilic acid derivatives for MRI contrast.
Patent # WO 2014182538 A1 20141113. | 01/01/2014

Yang X, Song X, Ray S, Pomper MG, McMahon M. 

Theranostic targeted nanoplexes which carry Multimodality imaging reporters together with target enzyme inhibitors, such as siRNAs and target prodrug enzymes, and their use in disease diagnosis and treatment.
Patent # US2014/0178399A1, WO 2012135592 A2 20121004 | 01/01/2014

Pomper MG, Bhujwalla Z, Chen Z, Li Cong, Nimmagadda S, Penet M-F; Ray, S

New homomultivalentevd heteromultivalent inhibitors of prostate specific membrane antigen (PSMA)
Patent # WO 2013082338 A1 20130606 | 01/01/2013

Pomper MG, Mease RC.; Ray S, Shallal, H. 

PSMA-targeted nanoparticles for therapy of prostate cancer.
Patent # US2011/02006779 | 01/01/2009

Chandran SS, Ray S, Denmeade SR, Pomper MG, Mease RC.

Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents
Patent # 9,044,468, WO2009/002529. | 01/01/2008

Pomper MG, Ray S, Mease RC, Foss C.

Contact for Research Inquiries

Division of Nuclear Medicine and Molecular Imaging (DNMMI)
Russell H. Morgan Department of Radiology and Radiological Sciences
1550 Orleans Street
Baltimore, MD 21287 map

Activities & Honors

Honors

  • BriteStar Award, JHU Radiology, 2019
  • Roger Tsien Award Finalist, World Molecular Imaging Congress, 2019
  • Career Development Award, Patrick Walsh Research foundation, 2015
  • Dr. and Mrs. Peter S. Bing Scholar, Patrick C. Walsh Prostate Cancer Research Fund, 2015
  • Travel stipend for the abstract “Gd-Based Magnetic Resonance Probes for Imaging Prostate Specific Membrane Antigen (PSMA), WMIC, 2013
  • Berson-Yalow Award, Society of Nuclear Medicine, 2011
  • Career Development Award, NIH NCI, 2011

Memberships

  • Member of the SNMMI WINM Program Working Group, 2016 - 2017
  • American Chemical Society, 2011
  • Society of Nuclear Medicine, 2011
  • World Molecular Imaging Society, 2011
  • American Association of Cancer Research, 2011
  • Society of Radiopharmaceutical Science, 2011

Professional Activities

  • Journal Reviewing Activities, 0
  • Editorial Activity, 0
  • Grant review, 0
  • Abstract reviewer, 0
  • Advisor, Precision Molecular Inc. (A JHU startup pharmaceutical company), 2019

Videos & Media

Lectures and Presentations

  • Metal-based prostate-specific membrane antigen (PSMA) inhibitors and their potential for cancer diagnosis and therapy.
    Presentation, ICMIC Seminar Series, Baltimore, MD (09/30/2009)
    Johns Hopkins University
  • Radiometal-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer
    Presentation, ICMIC Seminar Series, Baltimore, MD (10/16/2011)
    Johns Hopkins University
  • Design and synthesis of radiopharmaceuticals for SPECT Imaging. In vivo preclinical imaging: An introductory workshop
    Workshop, Society of Nuclear Medicine, Baltimore, MD (03/12/2012)
    Johns Hopkins University
  • Prostate-specific membrane antigen-based compounds for imaging and therapy of prostate cancer
    Presentation, ICMIC Seminar Series, Baltimore, MD (10/11/2012)
    Johns Hopkins University
  • PSMA Targeted Gd-Based MR/PET Contrast Agents for Imaging Prostate Cancer
    Presentation, NCI Alliance for Nanotechnology in Cancer, Houston, TX (10/17/2012)
    NCI Alliance for Nanotechnology in Cancer
  • Design and synthesis of radiometal-based imaging agents for prostate-specific membrane antigen (PSMA)
    Presentation, Chemistry Club, Baltimore, MD (01/08/2013)
    Brain Science Institute, Johns Hopkins University
  • Design and synthesis of radiopharmaceuticals for SPECT imaging. In vivo preclinical imaging: An introductory workshop, (Session Chair),
    Workshop, Baltimore, MD (03/11/2014)
    Society of Nuclear Medicine
  • Synthesis and evaluation of gadolinium-based contrast agents for MR imaging of prostate-specific membrane antigen (PSMA)
    Presentation (04/30/2014)
    ICMIC Seminar Series
  • Prostate-specific membrane antigen targeted nanoparticles for imaging and therapy of prostate cancer
    Presentation, National Science and Technology Innovation (Cancer Nanotechnology) Symposium, Gaylord Convention Center, Gaylord, MD (06/16/2014)
    TechConnect World 2014
  • Gd-Based MR Contrast Agents for Molecular Imaging of Prostate-Specific Membrane Antigen
    Presentation, 62nd SNMMI Annual Meeting, Baltimore, MD (06/08/2015)
    SNMMI
  • Low-molecular weight radiolabeled theranostic agents for metastatic castration- resistant prostate cancer
    Presentation, 11th Annual Johns Hopkins Prostate Research Day, Baltimore, MD (10/18/2016)
    Johns Hopkins University

Recent News Articles and Media Coverage

2015, SNM Scientific Press release on PSMA-based MR Imaging abstract at SNM annual meeting at Baltimore, MD.

2015, “Dr. and Mrs. Peter S. Bing Scholar”, Patrick C. Walsh Prostate Cancer Research Fund.

Is this you? Edit Profile
back to top button